After 4S, CARE and LIPID — is evidence-based medicine being practised?

This publication has 14 references indexed in Scilit:

• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
  European Heart Journal, 1998
• EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results
  European Heart Journal, 1997
• Frühbehandlung des akuten Myokardinfarktes: Umsetzung von Therapierichtlinien in den klinischen Alltag, MITRA-Pilotphase (Therapy of acute myocardial infarction, impact of clinical trials on clinical practice: The MITRA pilot phase)
  Clinical Research in Cardiology, 1997
• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
  New England Journal of Medicine, 1996
• Lipids, risk factors and ischaemic heart disease
  Atherosclerosis, 1996
• A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).
  Heart, 1996
• National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
  Circulation, 1994
• The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein
  Atherosclerosis, 1993
• Hospital Practice: STOPPING SMOKING AFTER MYOCARDIAL INFARCTION
  The Lancet, 1974